Health Law & Business News

Sanofi Loses Bid to Revive Two Patents on Lantus Insulin (1)

Nov. 19, 2019, 2:37 PM

Sanofi lost its appeals court bid to revive two patents on the Lantus insulin drug, eliminating an obstacle to Mylan NV’s proposed rival treatment.

The Patent Trial and Appeal Board was correct to invalidate the patents on the reformulation of the active ingredient in Lantus, the U.S. Court of Appeals for the Federal Circuit ruled in a 2-1 decision released Tuesday.

Lantus is a genetically engineered form of insulin known as insulin glargine that can act longer than natural human insulin. The drug is Sanofi’s biggest seller, with $3.6 billion in sales last year, almost 10% of the French...

To read the full article log in. To learn more about a subscription click here.